Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.

The Long Run with Luke Timmerman

Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Ep167: Leslie Williams on transfer RNA therapies

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ep165: Zach Hornby on Tackling Cancer Drug Resistance

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.

Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.

Ep162: Sean McClain on AI for Biologic Drug Discovery

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.

Ep161: Jeff Stein on a Long-Lasting Flu Drug

Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.

Ep160: Abe Ceesay on Precision Neuroscience

Science

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.